An Explorative Prospective Observational Study to Describe Morphokinetic De-selection Parameters in Human Embryos
1 other identifier
observational
738
1 country
1
Brief Summary
This post-marketing, multi-center prospective study will be conducted in a open-label, non-interventional setting, for women seeking fertility treatment and will describe morphokinetic de-selection parameters in human embryos.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2014
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 17, 2013
CompletedFirst Posted
Study publicly available on registry
December 23, 2013
CompletedStudy Start
First participant enrolled
January 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 12, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
May 12, 2016
CompletedAugust 28, 2017
August 1, 2017
2.1 years
December 17, 2013
August 25, 2017
Conditions
Outcome Measures
Primary Outcomes (4)
Incidence of direct cleavage from 1 to 3 and from 2 to 5 cells
1 week after oocyte retrieval
Incidence of uneven blastomeres at the 2 and 4 cell stage
1 week after oocyte retrieval
Incidence of bi- and multinucleation at 2 cell and 4 cell stage
1 week after oocyte retrieval
Incidence of Smooth Endoplasmatic Reticulum at the Metaphase II stage, the Pro Nuclei stage and the 2, 3 and 4 cell stage
1 week after oocyte retrieval
Secondary Outcomes (5)
Positive serum human Chorion Gonadotrophin (hCG) rate
13-15 days after transfer
Implantation rate
5 weeks after transfer
Clinical pregnancy rate
7 weeks after transfer
Ongoing pregnancy rate
10 weeks after transfer
Live birth rate
9 months
Study Arms (1)
Women treated with Menopur
Women treated with Menopur can participate with more than one cycle. 700 cycles will be enrolled.
Interventions
Eligibility Criteria
Women seeking fertility treatment
You may qualify if:
- Age 21-45 years
- In Vitro Fertilisation/Intra Cytoplasmic Sperm Injection treatment in long or short protocol
- Receiving follicle stimulation with Menopur 600/1200 IU
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fertilitetsklinikken Hospitalsenheden Horsens, Regionshospitalet Horsens (there may be other sites in this country)
Horsens, Denmark
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Clinical Development Support
Ferring Pharmaceuticals
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 17, 2013
First Posted
December 23, 2013
Study Start
January 1, 2014
Primary Completion
February 12, 2016
Study Completion
May 12, 2016
Last Updated
August 28, 2017
Record last verified: 2017-08